| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3997561 | Supportive Cancer Therapy | 2007 | 5 Pages |
Abstract
Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor–related rash.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
